The global research antibodies market was valued at USD 1.59 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 4.76% from 2024 to 2030. This growth is being driven by the increasing adoption of antibodies in various research applications, their critical role in immunological studies, and ongoing advancements in biomedical and therapeutic research.

Role of Antibodies in Research

Antibodies, produced primarily by B cells in the human immune system, are vital to many biological processes. They act as natural probes, able to recognize and bind to specific molecules, which makes them ideal tools for various research and diagnostic applications. These antibodies are used to identify, isolate, and quantify particular chemicals or molecules present in cells, tissues, or biological fluids, making them invaluable in areas such as molecular biology, immunology, and drug discovery.

Their ability to selectively bind to antigens allows researchers to track and manipulate biological pathways, helping scientists gain insights into disease mechanisms, immune responses, and cell signaling. As a result, the demand for antibodies in research and diagnostics is expected to continue to rise, with their use spanning a wide range of scientific disciplines, including cancer research, neuroscience, genetics, and infectious diseases.

Impact of COVID-19 on the Research Antibodies Market

The COVID-19 pandemic has had a profound impact on the research antibodies market. With the global health crisis spurring the need for rapid vaccine and therapeutic development, there has been a surge in demand for research antibodies. These antibodies play a crucial role in vaccine development, drug discovery, and diagnostic testing for infectious diseases, including COVID-19. The pandemic has not only heightened the need for novel antibodies but also created lucrative opportunities for companies and research institutions specializing in antibody-based solutions.

Pharmaceutical and biotechnology companies worldwide have significantly ramped up their research and development (RD) activities to create effective vaccines, treatments, and testing tools for COVID-19. Research antibodies are pivotal in these efforts, as they are used to produce diagnostic assays, screen for potential therapeutic antibodies, and test the immune response to vaccines. Consequently, the pandemic has acted as a catalyst for innovation and investment in the antibodies market.

Government and Private Sector Investments

Governments and private organizations are also playing a critical role in accelerating the development of COVID-19-related therapeutics and vaccines. For example, in April 2020, Emergent BioSolutions, a U.S.-based biopharmaceutical company, received a USD 14.5 million grant from the U.S. federal government to support an antibody therapy study for COVID-19. This funding is part of broader government efforts to support the development of effective treatments and vaccines, highlighting the growing demand for research antibodies to aid in the fight against the pandemic.

In addition to vaccine development, research antibodies are also integral in other aspects of the pandemic response, including the identification of potential COVID-19 treatments, the detection of viral proteins, and the monitoring of antibody responses in individuals who have recovered from the virus. The expanded use of antibodies in these applications has driven increased market opportunities for suppliers of high-quality research antibodies.

Regional Insights

North America:

In 2023, North America dominated the global research antibodies market, accounting for 39.15% of the total revenue share. The region's leadership in the market is largely driven by its strong focus on biomedical research, particularly in stem cells, cancer research, and immunology, where antibodies play a pivotal role. The presence of major market players like Thermo Fisher Scientific, Inc. and PerkinElmer, Inc., as well as numerous biotechnology and biopharmaceutical firms, bolsters the region's market share. These companies are heavily invested in life sciences innovation, driving demand for high-quality research antibodies.

In addition, the robust RD infrastructure and funding for scientific and medical research in North America contribute significantly to the region's growth. The U.S. and Canada are leading markets for the research antibodies industry, with their advanced healthcare systems, strong emphasis on precision medicine, and increasing government and private sector investments in biotechnology and pharmaceutical research.

The biotech sector in North America continues to thrive, with numerous biopharma companies focused on drug discovery and therapeutics development, including cancer treatments, vaccines, and autoimmune disease therapies. This contributes to a higher demand for research antibodies in both academic and commercial settings. The U.S. in particular is home to many top-tier universities and research institutions that drive innovation in antibody-based research.

Asia Pacific:

The Asia Pacific (APAC) region is expected to exhibit the fastest growth in the research antibodies market, with a CAGR forecasted from 2024 to 2030. This growth can be attributed to several factors, including the increased collaboration among academic institutions and research organizations across the region. Collaborative efforts in biomedical research and scientific advancements are significantly driving the demand for research antibodies.

For example, a research initiative involving scientists from Tsinghua University, China Medical University, and the Vaccine Research Center at the National Institutes of Health (NIH) is focused on the identification and characterization of HIV-1 strains and their resistance to neutralizing antibodies. This collaborative study is supported by several government-funded programs, including the National Natural Science Foundation of China, China's Ministry of Science and Technology, and the Gates Foundation Grand Challenges China. Such initiatives underscore the region's growing importance in global scientific research and are expected to drive demand for research antibodies.

Browse through Grand View Research's Category Biotechnology Industry Research Reports.

• The global exosomes market sizewas estimated at USD 177.4 million in 2024 and is anticipated to grow at a CAGR of 28.73% from 2025 to 2030. 

• The global automated and closed cell therapy processing systems market sizewas valued at USD 1.41 billion in 2024 and is projected to grow at a CAGR of 19.8% from 2025 to 2030. 

Key Research Antibodies Companies:

• Abcam Plc.
• Merck KGaA
• Thermo Fisher Scientific, Inc.
• Cell Signalling Technology, Inc.
• Santa Cruz Biotechnology Inc.
• PerkinElmer, Inc.
• Becton, Dickinson and Company
• Bio-Techne Corporation
• Proteintech Group, Inc.
• Jackson ImmunoResearch Inc.

Order a free sample PDF of the Market Intelligence Study, published by Grand View Research.